Minaris

Contract development and manufacturing organization Minaris has created a dedicated viral vectors business unit as part of a reorganization into three specialized divisions. The move signals a sharpened focus on distinct service areas, with viral vectors an increasingly important capability for cell and gene therapy production. Industry observers see it as part of broader consolidation and specialization trends across the CDMO sector.

Minaris, a contract development and manufacturing organization, announced it has evolved its business model by adding a dedicated viral vectors business unit. The reorganization is intended to sharpen the company's focus on viral vector services used in gene therapy and advanced biomanufacturing. Beyond the company's own announcement, no further details on structure, leadership or customer impact have been released.